TikoMed’s Board of Directors has appointed Dr Björn Pilström as Chief Executive Officer of TikoMed. Dr Pilström has an MD from Karolinska Institutet in Stockholm and a PhD in Immunology from Stockholm University. He has more than 25 years’ global experience from commercial, medical and managerial roles in the life
Senior consultant neurologist Dr Angelina Hatlø Maniaol is coordinating investigator for the study, which will consist of a 6-month double-blind randomized phase where patients will get either Riluzole or ILB®, followed by a 6-month open-label extension where patients will get both ILB® and Riluzole. The study is sponsored by Oslo
At the Annual General Meeting on 30 June 2025, TikoMed elected a new board of directors for the period until the next general meeting. The three members of the interim board elected in April this year will continue their assignments – Göran Groth as Chairman of the Board and Tobhias
Vid den ordinarie bolagsstämman den 30 juni 2025 valde TikoMed en ny styrelse för tiden fram till nästa bolagsstämma. De tre ledamöterna från interimsstyrelsen som valdes i april månad fortsätter sina uppdrag – Göran Groth som styrelseordförande och Tobhias Brandell och Lars Bruce som styrelseledamöter. Utöver dessa valde stämman in
Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed AB today announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB® is safe and well tolerated in patients with ALS. Eleven patients participated in the prospective, single-arm, open-label,
Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic